Investor Relations & Capital Introduction in Basel

Basel sits on the Rhine where Switzerland, France and Germany meet, and is one of the world's most important centres of pharmaceuticals and life sciences. For founders in biotechnology and health, it offers global corporate partners, specialist investors and deep scientific talent.

Why Basel Matters for Capital Raising

Novartis and Roche, two of the world's largest pharmaceutical companies, are both headquartered in Basel, and their corporate venture arms are active investors in biotechnology.

The Bank for International Settlements, founded in 1930 and often described as the central bank for central banks, is based in Basel, alongside a substantial private banking and wealth community.

The University of Basel, founded in 1460, is Switzerland's oldest university, and the city hosts Art Basel, one of the world's leading art fairs.

What Basel Investors Examine

For life sciences businesses, scientific data, clinical strategy and intellectual property are examined closely.

Investors value experienced teams and clear partnering or exit pathways with large pharmaceutical companies.

The Basel Startup and Investor Ecosystem

Basel's startup scene is built around the pharmaceutical and agricultural science companies that define the city. Beyond the large drug makers, Syngenta and Lonza have major operations here, and the Novartis Campus and the Roche towers anchor two of the city's main business districts. The ETH Zurich Department of Biosystems Science and Engineering, based in Basel, adds bioengineering research to the University of Basel's strengths in medicine and molecular biology.

Founders can draw on Switzerland Innovation Park Basel Area, which offers laboratory space for young life sciences companies, and BaseLaunch, a programme focused on early-stage therapeutics ventures. The regional economic promotion agency helps international companies establish themselves in the city.

Because Basel sits within a cross-border life sciences region reaching into Alsace and Baden, companies recruit talent and partners from three countries, while the deeper capital pools of Zurich are an easy rail journey away.

Investor Types Active in Basel

Basel is dominated by specialist capital: corporate venture arms of pharmaceutical and chemicals groups, dedicated biotechnology venture funds, and life sciences focused family offices built on generations of industrial wealth. Private banks and international crossover investors join larger rounds. These investors value rigorous scientific validation, experienced drug development leadership and assets that could interest a global pharmaceutical partner.

Engagement and Access

GCN connects founders with Basel life sciences investors, corporate venture funds and family offices through conference programming and private sessions across Switzerland.

Sectors where we see consistent Basel interest include biotechnology, pharmaceuticals, medical technology, digital health and chemicals.

Partner with Global Capital Network

Whether you are raising into Basel or allocating from it, our team can discuss how our investor relations infrastructure applies to your objectives.